Asosiy kontentga oʻtish
Maqola

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Caroline RobertInstitut Gustave RoussyGeorgina V. LongMelanoma Institute AustraliaBenjamin BradyCabrini Health, Melbourne, VICCaroline DutriauxThe authors' affiliations are listed in the AppendixMichele MaioThe authors' affiliations are listed in the AppendixLaurent MortierHôpital Claude Huriez, LilleJessica C. HasselUniversity Hospital HeidelbergPiotr RutkowskiMaria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, WarsawCatriona M. McNeilThe authors' affiliations are listed in the AppendixEwa Kalinka‐WarzochaThe authors' affiliations are listed in the AppendixKerry J. SavageBritish Columbia Cancer Agency, VancouverMicaela HernbergThe authors' affiliations are listed in the AppendixCélèste LebbéHôpital Saint-LouisJ. CharlesGrenoble University Hospital, INSERM Unité 823, Joseph Fourier University, GrenobleCatalin MihalcioiuThe authors' affiliations are listed in the AppendixVanna Chiarion‐SileniOncology Institute of Veneto Istituto di Ricovero e Cura a Carattere Scientifico, PaduaCornelia MauchDepartment of Dermatology, University Hospital Cologne and Centrum für Integrierte Onkologie Köln, BonnFrancesco CognettiThe authors' affiliations are listed in the AppendixAna AranceThe authors' affiliations are listed in the AppendixHenrik SchmidtDepartment of Oncology, Aarhus University Hospital, Aarhus, DenmarkDirk SchadendorfThe authors' affiliations are listed in the AppendixHelen GogasUniversity of Athens Medical School, Laiko General Hospital, AthensL. Lundgren-ErikssonThe authors' affiliations are listed in the AppendixChristine E. HorakThe authors' affiliations are listed in the AppendixBrian J. SharkeyThe authors' affiliations are listed in the AppendixIan M. WaxmanThe authors' affiliations are listed in the AppendixVictoria AtkinsonGallipoli Medical Research FoundationPaolo A. AsciertoIstituto Nazionale Tumori Fondazione Pascale, Naples
2014en
ABI

Annotatsiya

BACKGROUND: Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study. METHODS: We randomly assigned 418 previously untreated patients who had metastatic melanoma without a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks and dacarbazine-matched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched placebo every 2 weeks). The primary end point was overall survival. RESULTS: At 1 year, the overall rate of survival was 72.9% (95% confidence interval [CI], 65.5 to 78.9) in the nivolumab group, as compared with 42.1% (95% CI, 33.0 to 50.9) in the dacarbazine group (hazard ratio for death, 0.42; 99.79% CI, 0.25 to 0.73; P<0.001). The median progression-free survival was 5.1 months in the nivolumab group versus 2.2 months in the dacarbazine group (hazard ratio for death or progression of disease, 0.43; 95% CI, 0.34 to 0.56; P<0.001). The objective response rate was 40.0% (95% CI, 33.3 to 47.0) in the nivolumab group versus 13.9% (95% CI, 9.5 to 19.4) in the dacarbazine group (odds ratio, 4.06; P<0.001). The survival benefit with nivolumab versus dacarbazine was observed across prespecified subgroups, including subgroups defined by status regarding the programmed death ligand 1 (PD-L1). Common adverse events associated with nivolumab included fatigue, pruritus, and nausea. Drug-related adverse events of grade 3 or 4 occurred in 11.7% of the patients treated with nivolumab and 17.6% of those treated with dacarbazine. CONCLUSIONS: Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. (Funded by Bristol-Myers Squibb; CheckMate 066 ClinicalTrials.gov number, NCT01721772.).

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba